With only two targeted therapy options available for RET rearranged advanced non-small cell lung cancer, how do we select the best approach? Dr. Ross Camidge, the Director of the Thoracic Oncology Clinical and Clinical Research Programs at the University of Colorado, discusses treatment options for NSCLC.